Sol-Gel Technologies - 8 Year Stock Price History | SLGL
Historical daily share price chart and data for Sol-Gel Technologies since 2018 adjusted for splits and dividends. The latest closing stock price for Sol-Gel Technologies as of May 11, 2026 is 69.98.
- The all-time high Sol-Gel Technologies stock closing price was 171.50 on December 31, 2019.
- The Sol-Gel Technologies 52-week high stock price is 97.97, which is 40% above the current share price.
- The Sol-Gel Technologies 52-week low stock price is 6.80, which is 90.3% below the current share price.
- The average Sol-Gel Technologies stock price for the last 52 weeks is 41.31.
| Sol-Gel Technologies Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 72.8383 | 42.1500 | 97.9700 | 42.1500 | 69.9800 | 66.07% |
| 2025 | 17.8626 | 10.1500 | 44.5400 | 4.1000 | 42.1400 | 353.07% |
| 2024 | 8.0640 | 12.2010 | 16.5000 | 3.6600 | 9.3010 | -15.83% |
| 2023 | 30.2998 | 47.3000 | 53.2000 | 9.2020 | 11.0500 | -75.77% |
| 2022 | 59.5025 | 78.2000 | 82.1000 | 41.0000 | 45.5990 | -38.38% |
| 2021 | 102.3413 | 99.3000 | 154.9000 | 65.7000 | 74.0000 | -24.41% |
| 2020 | 88.3865 | 157.5000 | 157.5000 | 58.8000 | 97.9000 | -42.92% |
| 2019 | 80.4279 | 63.5000 | 171.5000 | 57.1000 | 171.5000 | 184.88% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.210B | $0.019B |
| Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |